shutterstock_1106804450_penpics_studio

PENpics Studio / Shutterstock.com

19 October 2021GenericsAlex Baldwin

Azurity sues Bionpharma over newly issued patent

Azurity Pharmaceuticals has sued Massachusetts drug company Bionpharma, claiming that its generic of Azurity’s Epaned product infringes on a brand new patent.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Apotex and Strides to merge Australia generics business

15 May 2018 Canadian generics maker Apotex and India-based Strides Shasun will merge their Australian operations in a bid to create the leading player in the Australian generics pharmaceutical market.

Eli Lilly targets more than 30 generics in Effient patent case

17 March 2014 Eli Lilly has filed suit against more than 30 generic drug makers at the US District Court for the Southern District of Indiana for allegedly infringing three patents related to platelet inhibitor drug Effient (prasugrel).

More on this story

Apotex and Strides to merge Australia generics business

15 May 2018 Canadian generics maker Apotex and India-based Strides Shasun will merge their Australian operations in a bid to create the leading player in the Australian generics pharmaceutical market.

Eli Lilly targets more than 30 generics in Effient patent case

17 March 2014 Eli Lilly has filed suit against more than 30 generic drug makers at the US District Court for the Southern District of Indiana for allegedly infringing three patents related to platelet inhibitor drug Effient (prasugrel).

More on this story

Apotex and Strides to merge Australia generics business

15 May 2018 Canadian generics maker Apotex and India-based Strides Shasun will merge their Australian operations in a bid to create the leading player in the Australian generics pharmaceutical market.

Eli Lilly targets more than 30 generics in Effient patent case

17 March 2014 Eli Lilly has filed suit against more than 30 generic drug makers at the US District Court for the Southern District of Indiana for allegedly infringing three patents related to platelet inhibitor drug Effient (prasugrel).

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB